Founder-led sales for B2B SaaS founders for healthcare and life sciences in Latin America

This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Latin America. In this market, LATAM buyers reward hands-on partnership, local presence, and clear commercial terms, so the way you install founder-led sales has to be shaped to that reality from day one.

If you are a B2B SaaS founder still under $5m ARR, founder-led sales is not something you delegate on day one. It is the founder personally running discovery, closing, and post-sale for the first 100 customers, and until it works you cannot describe your business without hand-waving.

The founder value in founder-led sales is that the founder is the fastest feedback loop between market and product. You bring context no hire can replicate — the reason you started the company, the exact objection you heard on call number seven, the phrase a customer used that finally clicked.

Own the strategy, the first 30 live cycles, and the weekly review. Delegate the tooling, the list building, and the reporting. Founders who invert that order end up hiring around a broken model.

Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Latin America it is compounded by the fact that local partnership depth, not marketing spend is what actually gates growth. Founder-led sales is only useful here when it is pointed at both constraints at once.

Instrument founder hours per week in customer conversations from day one — even if the number is embarrassing. You cannot debug what you do not measure, and every board meeting after Series A will start with this chart.

The founder trap in founder-led sales is hiring VP of Sales at $500k ARR to escape sales. It always looks reasonable at the time. Write the trap on a sticky note and stick it on your monitor.

The moment to hand off founder-led sales is when you can predict the number two weeks out and defend the assumptions behind it. Not before. VP hires that arrive earlier tend to leave inside 14 months.

Founders who take founder-led sales seriously in year one write category-defining companies in year three. The compounding is that stark.

Concretely for healthcare and life sciences in Latin America: the healthcare teams that install this get past procurement instead of dying in it, and one properly-installed LATAM account becomes a reference across the region. That is the reason it is worth installing founder-led sales deliberately for this market rather than importing a playbook designed for somewhere else.